Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression
Needham initiated coverage on Mind Medicine Inc. (NASDAQ:MNMD), or MindMed, on Monday. The late-stage clinical biopharmaceutical company is developing novel product candidates to treat brain health disorders.
Benzinga ·